Physician profile
Joy Ackles
NPI 1063771277
$3,934.99
in general payments reported to CMS, 2019-2025
28 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,730 · 2022: $937 · 2023: $513 · 2024: $493 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.87 | 2021-2025 | Creon, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $557.28 | 2021-2024 | Xifaxan, Trulance |
| Amgen INC. | $467.87 | 2021-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $343.92 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $308.95 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $277.79 | 2021-2025 | Airsupra |
| Daiichi Sankyo INC. | $192.33 | 2021-2023 | Injectafer |
| Pfizer INC. | $172.13 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.02 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $101.73 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $90.71 | 2023-2025 | Mounjaro, Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $88.64 | 2022 | |
| Amarin Pharma, INC. | $74.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $62.48 | 2021 | |
| Corcept Therapeutics | $46.00 | 2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.56 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $36.40 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $31.94 | 2025 | |
| Tandem Diabetes Care, INC. | $29.20 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Phadia US INC. | $26.84 | 2022 | |
| Sumitomo Pharma America, INC. | $21.28 | 2024 | Gemtesa |
| Medtronic, INC. | $19.91 | 2021 | |
| Mylan Specialty L.P. | $19.23 | 2021 | |
| Nevro Corp. | $18.57 | 2022 | |
| Edwards Lifesciences Corporation | $17.87 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Hologic Sales and Service, LLC | $17.54 | 2022 | |
| Verity Pharmaceuticals INC. | $16.81 | 2025 | Tlando |
| Alfasigma USA, INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Ackles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.